Brawn Biotech

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE899B01015
NSEID:
BSEID: 530207

INR

21.07

-0.43 (-2.0%)

BSENSE

Dec 19

BSE+NSE Vol: 171

{
  "main_header": {
    "sid": 479596,
    "name": "Brawn Biotech",
    "stock_name": "Brawn Biotech",
    "full_name": "Brawn Biotech Ltd",
    "name_url": "stocks-analysis/brawn-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "21.07",
    "chg": -0.43,
    "chgp": "-2.0%",
    "dir": -1,
    "prev_price": "21.50",
    "mcapval": "6.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530207,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE899B01015",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "171 ",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brawn-biotech-479596-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Brawn Biotech Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-stock-downgraded-to-sell-amid-mixed-technicals-and-weak-fundamentals-3754646",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrawnBiotech_mojoScore_3754646.png",
        "date": "2025-12-10 08:04:09",
        "description": "Brawn Biotech, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical indicators and fundamental financial data. While the company’s recent quarterly results reflect a flat performance, evolving technical trends and valuation considerations have influenced the overall analytical perspective on the stock."
      },
      {
        "title": "Brawn Biotech Sees Extraordinary Buying Interest Amid Upper Circuit Scenario",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brawn-biotech-hits-upper-circuit-amidst-unprecedented-buying-interest-3749195",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrawnBiotech_only_buyers_3749195.png",
        "date": "2025-12-05 15:35:22",
        "description": "Brawn Biotech has attracted remarkable buying interest, with the stock hitting the upper circuit and registering only buy orders in the queue. This unusual market activity signals a potential multi-day circuit scenario, underscoring strong demand despite recent underperformance against broader benchmarks."
      },
      {
        "title": "Brawn Biotech Surges to Upper Circuit Amid Unprecedented Buying Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brawn-biotech-hits-upper-circuit-amid-unprecedented-buying-interest-3746840",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrawnBiotech_only_buyers_3746840.png",
        "date": "2025-12-04 13:40:29",
        "description": "Brawn Biotech has witnessed extraordinary buying momentum today, hitting the upper circuit with a queue of only buy orders and no sellers in sight. This rare market phenomenon signals intense investor enthusiasm and raises the possibility of a multi-day circuit scenario for the pharmaceutical and biotechnology company."
      },
      {
        "title": "Brawn Biotech Sees Unprecedented Buying Interest Amid Upper Circuit Scenario",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brawn-biotech-hits-upper-circuit-amid-unprecedented-buying-interest-3744278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrawnBiotech_only_buyers_3744278.png",
        "date": "2025-12-03 12:31:08",
        "description": "Brawn Biotech has attracted extraordinary buying interest today, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals a strong demand surge, potentially setting the stage for a multi-day circuit scenario as sellers remain absent from the order book."
      },
      {
        "title": "Brawn Biotech Evaluation Metrics Reflect Mixed Signals Amidst Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-downgraded-to-strong-sell-amid-technical-and-fundamental-weaknesses-3737476",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrawnBiotech_mojoScore_3737476.png",
        "date": "2025-12-01 08:02:15",
        "description": "Brawn Biotech’s recent assessment reveals a complex picture shaped by flat quarterly financials, subdued long-term growth, and a shift in technical indicators. The pharmaceutical and biotechnology company’s current market performance and fundamental metrics highlight challenges amid a sideways technical trend, prompting a revision in the company’s evaluation across quality, valuation, financial trend, and technical parameters."
      },
      {
        "title": "How has been the historical performance of Brawn Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-brawn-biotech-3735981",
        "imagepath": "",
        "date": "2025-11-28 22:36:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>In the fiscal year ending March 2023, Brawn Biotech reported consolidated net sales of ₹0.48 crore, with no other operating income contributing to total operating income. The company’s expenditure closely matched its operating income, resulting in an operating profit margin excluding other income of 0.0%. However, other income of ₹0.24 crore helped the company achieve an operating profit (PBDIT) of ₹0.24 crore. After accounting for depreciation and taxes, the consolidated net profit stood at ₹0.19 crore, translating to a profit after tax (PAT) margin of 39.58%. Earnings per share (EPS) for the same period were ₹0.39, reflecting modest profitability relative to equity capital.</p>\n<p>Despite low sales figures, the company managed to maintain a ..."
      },
      {
        "title": "Brawn Biotech Sees Unprecedented Buying Interest Amid Upper Circuit Scenario",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brawn-biotech-hits-upper-circuit-amid-unprecedented-buying-interest-3733430",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrawnBiotech_only_buyers_3733430.png",
        "date": "2025-11-27 10:40:27",
        "description": "Brawn Biotech has captured market attention with extraordinary buying interest, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon highlights a potential multi-day circuit scenario, underscoring the stock’s unique position in the Pharmaceuticals & Biotechnology sector despite mixed performance trends over various time frames."
      },
      {
        "title": "Brawn Biotech Faces Intense Selling Pressure Amidst Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brawn-biotech-plunges-on-extreme-selling-pressure-amid-market-underperformance-3731414",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrawnBiotech_only_sellers_3731414.png",
        "date": "2025-11-26 12:30:28",
        "description": "Brawn Biotech Ltd has encountered significant selling pressure today, with the stock hitting its lower circuit and registering only sell orders in the queue. This extreme selling activity signals distress among investors, as the stock trades sharply below key moving averages and continues a pattern of underperformance relative to the broader market and its sector peers."
      },
      {
        "title": "Why is Brawn Biotech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-brawn-biotech-fallingrising-3721835",
        "imagepath": "",
        "date": "2025-11-22 00:25:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Brawn Biotech’s share price has been on a downward trajectory for the last four consecutive days, resulting in a cumulative loss of 14.58% during this period. This decline is particularly notable when compared to the benchmark Sensex, which has recorded a modest gain of 0.79% over the same one-week timeframe. The divergence highlights the stock’s underperformance relative to the broader market, signalling sector-specific or company-specific challenges that investors are currently weighing.</p>\n<p>Despite this short-term weakness, the stock has posted a positive return of 8.05% over the past month, slightly outperforming the Sensex’s 0.95% gain. However, the year-to-date figures reveal a different story, with Brawn Biotech down by 2.39%..."
      }
    ],
    "total": 412,
    "sid": "479596",
    "stock_news_url": "https://www.marketsmojo.com/news/brawn-biotech-479596"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "25-Nov-2025",
      "details": "Disclosure under regulation 30 of the SEBI (LODR) Regulations for resigantion of Director",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Nov-2025",
      "details": "Intimation of publication of unaudited financial result pursuant to regulation 47 of SEBI for second quarter and half year ended 30.09.2025",
      "source": "BSE"
    },
    {
      "caption": "Non Applicability For Filing Of Related Party Disclosure",
      "datetime": "17-Nov-2025",
      "details": "Non Applicability for filing of Related Party Disclosure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Brawn Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 18",
          "dt": "2018-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Brawn Biotech Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-10 08:04:09

Brawn Biotech, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical indicators and fundamental financial data. While the company’s recent quarterly results reflect a flat performance, evolving technical trends and valuation considerations have influenced the overall analytical perspective on the stock.

Brawn Biotech Sees Extraordinary Buying Interest Amid Upper Circuit Scenario

2025-12-05 15:35:22

Brawn Biotech has attracted remarkable buying interest, with the stock hitting the upper circuit and registering only buy orders in the queue. This unusual market activity signals a potential multi-day circuit scenario, underscoring strong demand despite recent underperformance against broader benchmarks.

Brawn Biotech Surges to Upper Circuit Amid Unprecedented Buying Interest

2025-12-04 13:40:29

Brawn Biotech has witnessed extraordinary buying momentum today, hitting the upper circuit with a queue of only buy orders and no sellers in sight. This rare market phenomenon signals intense investor enthusiasm and raises the possibility of a multi-day circuit scenario for the pharmaceutical and biotechnology company.

Brawn Biotech Sees Unprecedented Buying Interest Amid Upper Circuit Scenario

2025-12-03 12:31:08

Brawn Biotech has attracted extraordinary buying interest today, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals a strong demand surge, potentially setting the stage for a multi-day circuit scenario as sellers remain absent from the order book.

Brawn Biotech Evaluation Metrics Reflect Mixed Signals Amidst Flat Financials

2025-12-01 08:02:15

Brawn Biotech’s recent assessment reveals a complex picture shaped by flat quarterly financials, subdued long-term growth, and a shift in technical indicators. The pharmaceutical and biotechnology company’s current market performance and fundamental metrics highlight challenges amid a sideways technical trend, prompting a revision in the company’s evaluation across quality, valuation, financial trend, and technical parameters.

How has been the historical performance of Brawn Biotech?

2025-11-28 22:36:57

Revenue and Profitability Trends

In the fiscal year ending March 2023, Brawn Biotech reported consolidated net sales of ₹0.48 crore, with no other operating income contributing to total operating income. The company’s expenditure closely matched its operating income, resulting in an operating profit margin excluding other income of 0.0%. However, other income of ₹0.24 crore helped the company achieve an operating profit (PBDIT) of ₹0.24 crore. After accounting for depreciation and taxes, the consolidated net profit stood at ₹0.19 crore, translating to a profit after tax (PAT) margin of 39.58%. Earnings per share (EPS) for the same period were ₹0.39, reflecting modest profitability relative to equity capital.

Despite low sales figures, the company managed to maintain a ...

Brawn Biotech Sees Unprecedented Buying Interest Amid Upper Circuit Scenario

2025-11-27 10:40:27

Brawn Biotech has captured market attention with extraordinary buying interest, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon highlights a potential multi-day circuit scenario, underscoring the stock’s unique position in the Pharmaceuticals & Biotechnology sector despite mixed performance trends over various time frames.

Brawn Biotech Faces Intense Selling Pressure Amidst Consecutive Losses

2025-11-26 12:30:28

Brawn Biotech Ltd has encountered significant selling pressure today, with the stock hitting its lower circuit and registering only sell orders in the queue. This extreme selling activity signals distress among investors, as the stock trades sharply below key moving averages and continues a pattern of underperformance relative to the broader market and its sector peers.

Why is Brawn Biotech falling/rising?

2025-11-22 00:25:52

Recent Price Movement and Market Context

Brawn Biotech’s share price has been on a downward trajectory for the last four consecutive days, resulting in a cumulative loss of 14.58% during this period. This decline is particularly notable when compared to the benchmark Sensex, which has recorded a modest gain of 0.79% over the same one-week timeframe. The divergence highlights the stock’s underperformance relative to the broader market, signalling sector-specific or company-specific challenges that investors are currently weighing.

Despite this short-term weakness, the stock has posted a positive return of 8.05% over the past month, slightly outperforming the Sensex’s 0.95% gain. However, the year-to-date figures reveal a different story, with Brawn Biotech down by 2.39%...

View All News